Can Gliclazide 60 mg Be Given Twice Daily?
No, gliclazide modified release (MR) 60 mg should not be given twice daily—it is specifically formulated for once-daily administration. The modified release formulation uses a hydrophilic matrix polymer that provides progressive drug release over 24 hours, designed to match the glycemic profile throughout the day 1.
Dosing Guidance for Gliclazide
Modified Release (MR) Formulation
- Standard dosing: Gliclazide MR 60 mg is given once daily
- The dose can be titrated from 30 mg up to a maximum of 120 mg once daily 1
- Timing flexibility: Can be taken at any time of day, though consistency is recommended
- During Ramadan fasting, dosing should be switched from morning to evening (taken before the sunset meal/Iftar) 2, 3
Immediate Release (IR) Formulation
If you're considering twice-daily dosing, you would need to use the immediate release formulation of gliclazide (typically 80 mg tablets):
- Standard IR dosing: 80 mg twice daily (morning and evening) 2
- Maximum dose: 320 mg daily 4
- During Ramadan: Use half the usual morning dose at predawn meal (Suhur) and full dose at sunset meal (Iftar) 2
Key Clinical Considerations
The MR formulation offers distinct advantages over IR:
- Better 24-hour glycemic control with once-daily dosing 1
- Improved patient compliance due to simplified regimen 1
- Lower hypoglycemia risk compared to other sulfonylureas 5, 6
- No severe hypoglycemic events reported in real-world studies 3
If you need twice-daily sulfonylurea dosing, you have two options:
- Switch to gliclazide IR 80 mg twice daily
- Consider an alternative sulfonylurea that requires twice-daily dosing
Important safety note: When using any sulfonylurea twice daily, the hypoglycemia risk increases, particularly when combined with insulin or other insulin secretagogues 5. Patients should be counseled to take medication with meals and avoid skipping meals 7.
Context Within Current Guidelines
While sulfonylureas remain useful glucose-lowering agents 5, 8, current guidelines prioritize metformin as first-line therapy, with SGLT2 inhibitors or GLP-1 receptor agonists preferred for patients with established cardiovascular disease, heart failure, or chronic kidney disease 8, 9. Gliclazide MR specifically has demonstrated cardiovascular neutrality and glycemic durability 10, 6, making it a reasonable option when newer agents are contraindicated, not tolerated, or cost-prohibitive.